Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Verrica Pharmaceuticals develops dermatology treatments, including FDA-approved YCANTH (VP-102) for molluscum contagiosum, a contagious skin disease. The company focuses on clinician-administered therapies for high unmet needs, with pipeline products targeting common warts and dermatologic cancers like basal cell carcinoma. Its business model emphasizes innovative formulations, strategic licensing, and commercialization through specialized sales, targeting healthcare providers and patients worldwide.
This description was generated via AI from an annual report. Updated about 1 year ago.